Skip to main content

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Forecast 2025 - AI Price Prediction & Analysis


Ginkgo Bioworks Holdings, Inc. (DNA) AI Stock Price Forecast & Investment Analysis

Ginkgo Bioworks Holdings, Inc. Stock Price Chart and Technical Analysis

Loading Ginkgo Bioworks Holdings, Inc. interactive price chart and technical analysis...

Ginkgo Bioworks Holdings, Inc. (DNA) - Comprehensive Stock Analysis & Investment Research

Deep dive into Ginkgo Bioworks Holdings, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Ginkgo Bioworks Holdings, Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Ginkgo Bioworks Holdings, Inc.: Ginkgo Bioworks Holdings, Inc. operates in the Life Sciences sector, making it an emerging small-cap investment.

Ginkgo Bioworks Holdings, Inc. (Stock Symbol: DNA) is a leading company in the Life Sciences sector , specifically operating within the Biological Products, (No Diagnostic Substances) industry.

The organization employs approximately 1261 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Ginkgo Bioworks Holdings, Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Ginkgo Bioworks Holdings, Inc.: With $926M in annual revenue and -96.9% net margin, the company demonstrates developing profitability.

Annual Revenue: $926 million generating a -96.9% net profit margin .

Market Capitalization: $687 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -152.2% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Ginkgo Bioworks Holdings, Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Ginkgo Bioworks Holdings, Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Ginkgo Bioworks Holdings, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Ginkgo Bioworks Holdings, Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Ginkgo Bioworks Holdings, Inc.: Market positioning analysis based on available financial and operational metrics.

Ginkgo Bioworks Holdings, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company maintains a healthy 19.9% gross margin, indicating strong pricing power and operational efficiency.

Ginkgo Bioworks Holdings, Inc. (DNA) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Ginkgo Bioworks Holdings, Inc. stock analysis.

Loading Ginkgo Bioworks Holdings, Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into Ginkgo Bioworks Holdings, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Ginkgo Bioworks Holdings, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Ginkgo Bioworks Holdings, Inc.: With a P/E ratio of -13.93, the market sees the stock as potentially undervalued.

P/E Ratio -13.93x
P/B Ratio 0.40x
Market Cap $687M
EPS $-1.37
Book Value/Share $31.31
Revenue/Share $0.09
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Ginkgo Bioworks Holdings, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Ginkgo Bioworks Holdings, Inc.: An ROE of -152.2% indicates room for improvement in shareholder value creation.

ROE -152.2%
ROA -116.9%
ROIC -149.5%
Gross Margin 19.9%
Operating Margin -93.4%
Net Margin -96.9%
EBT Margin -537.7%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Ginkgo Bioworks Holdings, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Ginkgo Bioworks Holdings, Inc.: A current ratio of 10.71 indicates strong liquidity.

Current Ratio 10.71x
Quick Ratio 10.45x
D/E Ratio 0.02x
Financial Leverage 1.30x
Interest Coverage -773.6x
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Ginkgo Bioworks Holdings, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Ginkgo Bioworks Holdings, Inc.: Free cash flow of $-264M indicates cash challenges that need attention.

Operating Cash Flow $-226M
Free Cash Flow $-264M
Capital Spending $-38M
FCF/Sales -60.2%
CapEx/Sales 8.7%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Ginkgo Bioworks Holdings, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Ginkgo Bioworks Holdings, Inc.: An asset turnover of 0.21x suggests room for improvement in asset utilization.

Asset Turnover 0.21x
Receivables Turnover 2.6x
Inventory Turnover 22.0x
Fixed Assets Turnover 2.9x
Days Sales Outstanding 143 days
Days Inventory 17 days
Payables Period 67 days
Cash Conversion Cycle 92 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Ginkgo Bioworks Holdings, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Ginkgo Bioworks Holdings, Inc.: With annual revenue of $926M, Ginkgo Bioworks Holdings, Inc. demonstrates solid business size.

Income Statement ($ Millions)
Total Revenue $926M
Operating Income $-5M
Net Income $-256M
R&D Expense $465M
SG&A Expense $292M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 83%
Cash & Short-term Investments 73%
Total Liabilities 22%
Accounts Receivable 8%
Inventory 0%
Dividend & Shareholder Information
Shares Outstanding 55M
Growth Metrics (YoY)
EPS Growth -12.0%

Latest Ginkgo Bioworks Holdings, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Ginkgo Bioworks Holdings, Inc. (DNA) stock price and investment outlook.

Ginkgo Bioworks Holdings, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Ginkgo Bioworks Holdings, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS Unlock Forecast - 30 Days FREE Trial $123M -1.9x 1.1x
ABP Unlock Forecast - 30 Days FREE Trial $13M x 0.0x
ACLX Unlock Forecast - 30 Days FREE Trial $4764M -74.1x 12.1x
ACOG Unlock Forecast - 30 Days FREE Trial $110M x 3.5x
ADAP Unlock Forecast - 30 Days FREE Trial $318M -13.2x -11.8x
ADMA Unlock Forecast - 30 Days FREE Trial $3705M 17.3x 9.3x
ADPT Unlock Forecast - 30 Days FREE Trial $2558M -4.6x 14.2x
AGEN Unlock Forecast - 30 Days FREE Trial $116M -0.5x -0.5x
AIM Unlock Forecast - 30 Days FREE Trial $2M -0.5x -183.3x
AIMI Unlock Forecast - 30 Days FREE Trial $2M x x
ALEC Unlock Forecast - 30 Days FREE Trial $154M -1.2x 2.2x
ALGS Unlock Forecast - 30 Days FREE Trial $61M -19.2x 0.6x
ALLO Unlock Forecast - 30 Days FREE Trial $266M -1.4x 0.8x
AMGN Unlock Forecast - 30 Days FREE Trial $157060M 23.8x 21.1x
APGE Unlock Forecast - 30 Days FREE Trial $3262M -20.5x 4.3x
APTOF Unlock Forecast - 30 Days FREE Trial $4M x x
ARMP Unlock Forecast - 30 Days FREE Trial $123M -1.0x -1.6x
ARTV Unlock Forecast - 30 Days FREE Trial $132M x 0.9x
ATHA Unlock Forecast - 30 Days FREE Trial $143M -0.2x 4.5x
ATRA Unlock Forecast - 30 Days FREE Trial $103M 17.8x -1.1x
AURA Unlock Forecast - 30 Days FREE Trial $377M -4.9x 2.2x
AUTL Unlock Forecast - 30 Days FREE Trial $403M x 1.2x
AVXL Unlock Forecast - 30 Days FREE Trial $700M -17.3x 7.7x
BCLI Unlock Forecast - 30 Days FREE Trial $7M -4.9x -0.9x
BCRX Unlock Forecast - 30 Days FREE Trial $1534M -12.1x -4.0x
BDTX Unlock Forecast - 30 Days FREE Trial $228M 15.8x 1.7x
BEAM Unlock Forecast - 30 Days FREE Trial $2496M -12.6x 2.4x
BIIB Unlock Forecast - 30 Days FREE Trial $21691M 14.4x 1.5x
CABA Unlock Forecast - 30 Days FREE Trial $226M -1.6x 1.3x
CADL Unlock Forecast - 30 Days FREE Trial $306M -4.6x 3.4x
CCCC Unlock Forecast - 30 Days FREE Trial $174M -2.6x 1.0x
CDTX Unlock Forecast - 30 Days FREE Trial $2432M -1.0x 4.9x
CELZ Unlock Forecast - 30 Days FREE Trial $9M -3.4x 1.4x
CERO Unlock Forecast - 30 Days FREE Trial $1M x -196.2x
CGEM Unlock Forecast - 30 Days FREE Trial $447M -4.1x 0.9x
CGEN Unlock Forecast - 30 Days FREE Trial $176M x 3.5x
CGON Unlock Forecast - 30 Days FREE Trial $3276M x 4.9x
CGTX Unlock Forecast - 30 Days FREE Trial $113M -0.5x 16.1x
CHRS Unlock Forecast - 30 Days FREE Trial $192M 1.1x 1.6x
CLDI Unlock Forecast - 30 Days FREE Trial $5M -0.9x 2.6x
CMPX Unlock Forecast - 30 Days FREE Trial $519M -4.8x 5.6x
CRBU Unlock Forecast - 30 Days FREE Trial $216M -1.5x 1.3x
CRDF Unlock Forecast - 30 Days FREE Trial $148M -4.0x 2.5x
CRIS Unlock Forecast - 30 Days FREE Trial $16M -0.3x -2.9x
CRSP Unlock Forecast - 30 Days FREE Trial $5529M -12.1x 3.2x
CVM Unlock Forecast - 30 Days FREE Trial $47M -0.9x 6.7x
DBVT Unlock Forecast - 30 Days FREE Trial $1930M -3.3x 36.5x
DNA Unlock Forecast - 30 Days FREE Trial $687M -13.9x 0.4x
DNLI Unlock Forecast - 30 Days FREE Trial $2367M -8.7x 2.3x
DTIL Unlock Forecast - 30 Days FREE Trial $78M -2.2x 2.3x
EDIT Unlock Forecast - 30 Days FREE Trial $263M -0.8x 13.7x
ELUT Unlock Forecast - 30 Days FREE Trial $40M -1.4x -0.1x
ENGN Unlock Forecast - 30 Days FREE Trial $371M 3.7x 1.9x
ENTX Unlock Forecast - 30 Days FREE Trial $107M 8.5x 6.2x
ESLA Unlock Forecast - 30 Days FREE Trial $65M -3.1x -16.9x
EXEL Unlock Forecast - 30 Days FREE Trial $10651M 17.1x 5.2x
EXOZ Unlock Forecast - 30 Days FREE Trial $106M x 14.7x
FATE Unlock Forecast - 30 Days FREE Trial $169M -1.3x 0.7x
FDMT Unlock Forecast - 30 Days FREE Trial $527M -3.0x 1.3x
FENC Unlock Forecast - 30 Days FREE Trial $229M 1758.3x -39.7x
FNCH Unlock Forecast - 30 Days FREE Trial $19M -0.1x 1.4x
FTII Unlock Forecast - 30 Days FREE Trial $3M x -0.7x
FTIIU Unlock Forecast - 30 Days FREE Trial $-26M x -0.8x
GILD Unlock Forecast - 30 Days FREE Trial $147177M 23.8x 7.5x
GLUE Unlock Forecast - 30 Days FREE Trial $805M 23.0x 3.0x
GNTA Unlock Forecast - 30 Days FREE Trial $58M x 4.7x
GPLB Unlock Forecast - 30 Days FREE Trial $1M x x
HALO Unlock Forecast - 30 Days FREE Trial $7676M 14.0x 23.1x
HLVX Unlock Forecast - 30 Days FREE Trial $105M -0.6x 0.7x
HUMA Unlock Forecast - 30 Days FREE Trial $253M -3.3x 62.5x
IBRX Unlock Forecast - 30 Days FREE Trial $2216M -3.6x -4.1x
IKT Unlock Forecast - 30 Days FREE Trial $115M -1.0x 1.4x
IMCR Unlock Forecast - 30 Days FREE Trial $1655M x 4.3x
IMVT Unlock Forecast - 30 Days FREE Trial $3704M -14.5x 6.1x
INBX Unlock Forecast - 30 Days FREE Trial $1131M -6.8x 16.5x
INKT Unlock Forecast - 30 Days FREE Trial $56M -1.5x -1.4x
INMB Unlock Forecast - 30 Days FREE Trial $49M -2.5x 1.7x
INTS Unlock Forecast - 30 Days FREE Trial $7M -2.2x 3.1x
IOVA Unlock Forecast - 30 Days FREE Trial $694M -4.5x 1.0x
IPSC Unlock Forecast - 30 Days FREE Trial $50M -0.7x 0.2x
IVVD Unlock Forecast - 30 Days FREE Trial $225M -0.4x 5.3x
JSPR Unlock Forecast - 30 Days FREE Trial $40M -3.2x 1.7x
KLRS Unlock Forecast - 30 Days FREE Trial $87M x 1.6x
KLTO Unlock Forecast - 30 Days FREE Trial $32M x 3.0x
KOD Unlock Forecast - 30 Days FREE Trial $1054M -2.5x 15.0x
KRYS Unlock Forecast - 30 Days FREE Trial $5353M 36.7x 5.1x
KYMR Unlock Forecast - 30 Days FREE Trial $4236M -17.8x 4.4x
KYTX Unlock Forecast - 30 Days FREE Trial $292M x 1.6x
LADX Unlock Forecast - 30 Days FREE Trial $0M x x
LCTX Unlock Forecast - 30 Days FREE Trial $419M -4.7x 8.7x
LENZ Unlock Forecast - 30 Days FREE Trial $873M -6.7x 4.2x
LIMN Unlock Forecast - 30 Days FREE Trial $0M x x
LXEO Unlock Forecast - 30 Days FREE Trial $509M -0.4x 3.7x
MAZE Unlock Forecast - 30 Days FREE Trial $1408M x 5.4x
MGTX Unlock Forecast - 30 Days FREE Trial $716M -3.4x 241.9x
MGX Unlock Forecast - 30 Days FREE Trial $108M x 0.6x
MRNA Unlock Forecast - 30 Days FREE Trial $9608M -3.2x 1.0x
NBIX Unlock Forecast - 30 Days FREE Trial $13761M 40.8x 4.6x
NMRA Unlock Forecast - 30 Days FREE Trial $473M -3.9x 2.6x
NVAX Unlock Forecast - 30 Days FREE Trial $1348M 3.2x 35.8x
OCGN Unlock Forecast - 30 Days FREE Trial $432M -4.3x 141.7x
PASG Unlock Forecast - 30 Days FREE Trial $26M -0.6x 0.7x
PCVX Unlock Forecast - 30 Days FREE Trial $5650M -20.4x 1.8x
PHGE Unlock Forecast - 30 Days FREE Trial $15M 1.5x 0.8x
PLUR Unlock Forecast - 30 Days FREE Trial $34M -1.4x -9.1x
PLX Unlock Forecast - 30 Days FREE Trial $144M 23.0x 2.9x
PRME Unlock Forecast - 30 Days FREE Trial $603M -1.5x 9.9x
PROK Unlock Forecast - 30 Days FREE Trial $198M x 0.0x
QGEN Unlock Forecast - 30 Days FREE Trial $10604M x 3.0x
QNCX Unlock Forecast - 30 Days FREE Trial $100M -1.7x 8.5x
REPL Unlock Forecast - 30 Days FREE Trial $809M -3.8x 2.4x
RGEN Unlock Forecast - 30 Days FREE Trial $8352M 8219.1x 4.1x
RGNX Unlock Forecast - 30 Days FREE Trial $657M -1.8x 3.1x
RLAY Unlock Forecast - 30 Days FREE Trial $1242M -2.0x 1.9x
RVMD Unlock Forecast - 30 Days FREE Trial $10844M -11.1x 5.8x
RXRX Unlock Forecast - 30 Days FREE Trial $2541M -4.7x 2.8x
SANA Unlock Forecast - 30 Days FREE Trial $1203M -2.1x 9.8x
SCLX Unlock Forecast - 30 Days FREE Trial $90M -0.4x -0.3x
SCNI Unlock Forecast - 30 Days FREE Trial $8479M -287.8x 1079.1x
SGMO Unlock Forecast - 30 Days FREE Trial $137M -1.6x 7.0x
SLDB Unlock Forecast - 30 Days FREE Trial $417M -0.9x 1.6x
SLXN Unlock Forecast - 30 Days FREE Trial $2M x 17.0x
SRRK Unlock Forecast - 30 Days FREE Trial $2810M -18.5x 12.0x
SRZN Unlock Forecast - 30 Days FREE Trial $116M -0.5x 2.5x
STRO Unlock Forecast - 30 Days FREE Trial $86M -1.0x -2.5x
TARA Unlock Forecast - 30 Days FREE Trial $212M -2.1x 1.5x
TARS Unlock Forecast - 30 Days FREE Trial $2850M -12.4x 8.6x
TCBPY Unlock Forecast - 30 Days FREE Trial $13M x 11.8x
TCRX Unlock Forecast - 30 Days FREE Trial $300M -4.6x 1.7x
TECX Unlock Forecast - 30 Days FREE Trial $329M -8.9x 1.2x
TNYA Unlock Forecast - 30 Days FREE Trial $247M -2.5x 2.5x
TRML Unlock Forecast - 30 Days FREE Trial $1233M -3.5x 4.8x
TSHA Unlock Forecast - 30 Days FREE Trial $1392M -3.0x 5.6x
TVGN Unlock Forecast - 30 Days FREE Trial $136M x -29.3x
TWST Unlock Forecast - 30 Days FREE Trial $1938M -12.6x 4.1x
VACH Unlock Forecast - 30 Days FREE Trial $66M x 0.0x
VACHU Unlock Forecast - 30 Days FREE Trial $67M x 0.0x
VCEL Unlock Forecast - 30 Days FREE Trial $1759M 257.8x 5.7x
VIR Unlock Forecast - 30 Days FREE Trial $841M -2.0x 0.9x
VOR Unlock Forecast - 30 Days FREE Trial $3141M -0.6x 3.9x
VXRT Unlock Forecast - 30 Days FREE Trial $82M -0.9x 2.5x
VYGR Unlock Forecast - 30 Days FREE Trial $258M 570.6x 1.1x
ZIVO Unlock Forecast - 30 Days FREE Trial $48M -31.3x -2.0x

Frequently Asked Questions - Ginkgo Bioworks Holdings, Inc. Stock Forecast

How accurate are Ginkgo Bioworks Holdings, Inc. stock predictions?

Our AI model shows a 53% Spearman correlation coefficient for DNA predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Ginkgo Bioworks Holdings, Inc. stock price forecasts?

Our analysis considers Ginkgo Bioworks Holdings, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Ginkgo Bioworks Holdings, Inc. a good investment in 2025?

Based on our AI analysis, Ginkgo Bioworks Holdings, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Ginkgo Bioworks Holdings, Inc. forecasts updated?

Ginkgo Bioworks Holdings, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Ginkgo Bioworks Holdings, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Ginkgo Bioworks Holdings, Inc. stock.

My Portfolio

Investment Dashboard

Loading your portfolio...